> The Epilepsy Prescriber's Guide to Antiepileptic Drugs

The Epilepsy Prescriber's Guide to Antiepileptic Drugs

Philip N. Patsalos

FRCPath, PhD Professor of Clinical Pharmacology & Consultant Clinical Pharmacologist UCL Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, and the National Society for Epilepsy, Chalfont St Peter, UK

and

Blaise F.D. Bourgeois

MD

Professor of Neurology, Harvard Medical School Director, Division of Epilepsy and Clinical Neurophysiology William G. Lennox Chair in Pediatric Epilepsy Children's Hospital Boston, USA



CAMBRIDGE UNIVERSITY PRESS Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo, Delhi, Dubai, Tokyo

Cambridge University Press The Edinburgh Building, Cambridge CB2 8RU, UK

Published in the United States of America by Cambridge University Press, New York

www.cambridge.org Information on this title: www.cambridge.org/9780521687164

© P. N. Patsalos and B. F. D. Bourgeois 2010

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2010

Printed in the United Kingdom at the University Press, Cambridge

A catalog record for this publication is available from the British Library

Library of Congress Cataloging in Publication data
Patsalos, P. N. (Philip N.)
The epilepsy prescriber's guide to antiepileptic drugs / Philip N. Patsalos and Blaise F.D. Bourgeois.
p.; cm.
Includes bibliographical references and index.
ISBN 978-0-521-68716-4 (pbk.)
1. Anticonvulsants-Handbooks, manuals, etc. 2. Epilepsy-Chemotherapy-Handbooks, manuals, etc. 1. Bourgeois, Blaise F.D. II. Title.
[DNLM: 1. Anticonvulsants-Handbooks. 2. Epilepsy-drug therapy-Handbooks.
QV 39 P314e 2010]
RM322.P38 2010
616.8'53061-dc22 2010016393

ISBN 978-0-521-68716-4 Paperback

Additional resources for this publication at www.cambridge.org/9780521687164

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. The authors, editors, and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors, and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

CONTENTS

Preface	page vii
Introduction	ix
Acetazolamide	1
ACTH	11
Carbamazepine	19
Clobazam	31
Clonazepam	40
Diazepam	49
Eslicarbazepine acetate	59
Ethosuximide	68
Felbamate	77
Fosphenytoin	86
Gabapentin	95
Lacosamide	104
Lamotrigine	111
Levetiracetam	124
Lorazepam	134
Methsuximide	145
Midazolam	153
Oxcarbazepine	163
Paraldehyde	173
Phenobarbital	181
Phenytoin	192
Piracetam	204
Pregabalin	212
Primidone	220
Rufinamide	230
Stiripentol	238
Sulthiame	246
Tiagabine	255
Topiramate	263
Valproate	274
Vigabatrin	288
Zonisamide	297
Abbreviations	307
Interaction Table	308
Index	310

v

PREFACE

With the rapidly increasing number of available antiepileptic drugs to choose from, those involved in any aspect of the treatment of patients with epilepsy face the challenge of remaining familiar with all relevant aspects of every medication that is currently available, including the newest ones. The purpose of *The Epilepsy Prescriber's Guide to Antiepileptic Drugs* is to present all the necessary information in a format that allows the prescriber to easily and rapidly find the specific answer to any question that may arise in the process of initiating and monitoring a medication for the treatment of epilepsy. As opposed to standard textbooks, this unique guide focuses, in a systematic and didactic manner, on all the information that the prescriber will need to choose and use a medication, as well as on features of the drug that may need to be discussed with the patient before or during treatment.

The topics covered for each drug follow an identical sequence and include chemical name and structure; brand names in major countries; generics available; licensed indications; nonlicensed use; seizure types for which the drug is ineffective or contraindicated; mechanism of action; pharmacokinetic parameters; interaction profile; common, lifethreatening, or dangerous adverse effects; dosing and use; laboratory monitoring; use in special populations (renal and hepatic impairment, children, the elderly, pregnant, and breast-feeding women); the overall place of the drug in the treatment of epilepsy; suggested reading.

The reader can use this guide in many different ways and for various purposes, such as to rapidly review a synopsis of all relevant aspects of a given drug, to choose a drug for a patient by reviewing the spectrum of efficacy and adverse effects of several drugs, to find the answer to one specific question about a specific drug, or as a guide to discuss precautions and adverse effects with a patient before or during treatment. In all instances, this information will be rapidly and easily found.

INTRODUCTION

The purpose of *The Epilepsy Prescriber's Guide to Antiepileptic Drugs* (AEDs) is to provide practical and concise information so as to allow the optimum use of AEDs in clinical practice. This quick reference guide provides a wealth of invaluable information for use by all who treat patients with epilepsy, including neurologists, neurosurgeons, general physicians, those caring for the elderly, emergency medicine doctors, medical students and trainees at all levels, general practitioners, nurses and epilepsy nurse specialists, and practice pharmacists.

All of the drugs are presented in the same design format and in alphabetical order to facilitate rapid access to information. Specifically, each drug is divided into eight sections and each section is designated by a unique color background: therapeutics, pharmacokinetics, drug interaction profile, adverse effects, dosing and use, special populations, and the overall place of the drug in the treatment of epilepsy, followed by suggested reading of key references.

Section 1: Therapeutics

Covers the chemical name and structure; brand names in major countries; generics available; licensed indications as approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) or the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA); nonlicensed use; seizure types for which the drug is ineffective or contraindicated; mechanism of action; efficacy profile.

Section 2: Pharmacokinetics

Highlights the pharmacokinetic parameters relevant to each drug's clinical therapeutics and includes absorption and distribution, metabolism, and elimination parameters.

Section 3: Drug interaction profile

The interaction profile of each drug is divided into three major sections which include pharmacokinetic interactions, pharmacodynamic interactions, and interaction with hormonal contraception. The pharmacokinetic interaction section is further subdivided into interactions between AEDs and interactions between AEDs and non-AED drugs. Noninteracting drugs have been omitted.

Section 4: Adverse effects

Explains how the drug causes adverse effects; contains a list of common, life-threatening, or dangerous adverse effects; an effect on weight is noted, and advice about what to do about adverse effects.

Section 5: Dosing and use

Provides the usual dosing range; available formulations; how to dose and dosing tips; how to withdraw drug; symptoms of overdose and how to

INTRODUCTION

THE EPILEPSY PRESCRIBER'S GUIDE TO ANTIEPILEPTIC DRUGS

manage; what tests and therapeutic drug monitoring are needed; other warnings and precautions; and when not to use.

Section 6: Special populations

Gives information about use of the drugs in the presence of renal and hepatic impairments, and any precautions to be taken for treating children, the elderly, and pregnant and breast-feeding women.

Section 7: The overall place of the drug in the treatment of epilepsy

This section provides an overview, based on the authors' opinions, as to where each AED can be placed in relation to the treatment of patients with epilepsy and summarizes the primary and secondary seizure types for which it shows efficacy, and finally highlights the potential advantages and disadvantages of each AED.

Section 8: Suggested reading

In this section, the authors highlight the key references that were used in compiling the information contained in each drug section and readers are advised to read these if more information is needed. Readers are also encouraged to consult standard comprehensive reference books on epilepsy and AED textbooks for more in-depth information.

At the back of the guide is an index by drug name. In addition, there is a list of abbreviations and a table highlighting the interactions that can occur between the different AEDs.